← Back to Search

Joint Replacement

Hip Resurfacing for Arthritis (BHR Trial)

N/A

Waitlist Available

Led By Edwin Su, MD

Research Sponsored by Smith & Nephew, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

At least 21 years of age and skeletally mature

Patients requiring primary hip resurfacing due to non-inflammatory arthritis such as osteoarthritis, traumatic arthritis, avascular necrosis, or dysplasia/DDH

Must not have

Subjects with infection or sepsis

Subjects with bone stock inadequate to support the device

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Summary

This trial will evaluate the long-term safety and effectiveness of the BHR system in patients with arthritis.

Who is the study for?

This trial is for adults over 21 with arthritis needing hip resurfacing, who can follow up for ten years. It's not for those with infections, severe muscle or nerve diseases, poor bone quality, metal allergies, women of childbearing age, the immunosuppressed or severely overweight individuals.

What is being tested?

The study tests the long-term safety and effectiveness of the Birmingham Hip Resurfacing (BHR) System in patients with various types of arthritis including osteoarthritis and rheumatoid arthritis.

What are the potential side effects?

While specific side effects are not listed here, typical risks may include pain at the surgery site, infection risk from surgery, possible reaction to materials used in BHR system if there's a metal sensitivity.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 21 or older and my bones have stopped growing.

Select...

I need hip resurfacing due to arthritis or hip damage not caused by inflammation.

Select...

I need hip surgery due to arthritis like rheumatoid arthritis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I currently have an infection or sepsis.

Select...

My bones are too weak to support a medical device.

Select...

I have moderate to severe kidney problems.

Select...

I have a weakened immune system due to AIDS or I'm taking high doses of steroids.

Select...

I am severely overweight.

Select...

I do not have severe vascular, muscle, or nerve conditions that could affect surgery recovery.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups

Experimental Treatment

Group I: Hip ResurfacingExperimental Treatment1 Intervention

Birmingham Hip Resurfacing

0 / 9Eligibility criteria met

Find a Location

Who is running the clinical trial?

Smith & Nephew, Inc.Lead Sponsor

167 Previous Clinical Trials

21,748 Total Patients Enrolled

16 Trials studying Arthritis

1,672 Patients Enrolled for Arthritis

Edwin Su, MDPrincipal InvestigatorHospital for Special Surgery, New York

1 Previous Clinical Trials

200 Total Patients Enrolled

Christopher Drinkwater, MDPrincipal InvestigatorUniversity of Rochester

Media Library

Birmingham Hip Resurfacing System (Joint Replacement) Clinical Trial Eligibility Overview. Trial Name: NCT00611585 — N/A

Arthritis Research Study Groups: Hip Resurfacing

Arthritis Clinical Trial 2023: Birmingham Hip Resurfacing System Highlights & Side Effects. Trial Name: NCT00611585 — N/A

Birmingham Hip Resurfacing System (Joint Replacement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00611585 — N/A

~39 spots leftby Dec 2026

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.